Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.56 |
| ▸ | PREP | P48147 | 1/20 | 0.56 |
| ▸ | FAP | Q12884 | 1/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772871 | 1.00 | DPP4 (0.56) | DPP4PREPFAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL29548868 | 0.98 | DPP4 (0.54) | DPP4PREPFAPDPP8DPP9 | |
| Bromide SCHEMBL9464510 | 0.98 | DPP4 (0.54) | DPP4PREPFAPDPP8DPP9 | |
| Bromide SCHEMBL9464396 | 0.98 | DPP4 (0.54) | DPP4PREPFAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL19692659 | 0.98 | DPP4 (0.54) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL10884099 | 0.85 | DPP4 (0.54) | DPP4ACEHTR1AHTR7 | |
| SCHEMBL1493753 | 0.85 | DPP4 (0.47) | DPP4ACEHTR1AHTR7 | |
| Glycyl Proline SCHEMBL155067 | 0.85 | ACE (0.62) | DPP4PREPFAPDPP8DPP9 | |
| Glycyl Proline SCHEMBL30051559 | 0.85 | ACE (0.62) | DPP4PREPFAPDPP8DPP9 | |
| Glycyl Proline SCHEMBL155066 | 0.85 | ACE (0.62) | DPP4PREPFAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5599791-A | BACTERICIDE ACTIVE AGAINST GRAMNEGATIVE AND GRAMPOSITIVE BACTERIA | GRUPPO LEPETIT SPA (IT) | 1997-02-04 | — | — | US | claimed |
| WO-1992012172-A9 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS | — | 1996-04-04 | — | — | WO | claimed |
| EP-0565567-B1 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS | LEPETIT SPA (IT) | 1995-01-18 | — | — | EP | claimed |
| EP-0565567-A1 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS. | LEPETIT SPA (IT) | 1993-10-20 | — | — | EP | claimed |
| WO-1992012172-A1 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS | GRUPPO LEPETIT S.P.A. (IT) | 1992-07-23 | — | — | WO | claimed |
| EP-0494078-A1 | Amides of antibiotic ge 2270 factors | GRUPPO LEPETIT S.p.A. (IT) | 1992-07-08 | — | — | EP | claimed |
| US-11529338-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2021-06-03 | — | — | US | disclosed |
| US-10927070-B2 | Compositions and methods for treating cancer | CEDARS-SINAI MEDICAL CENTER (US) | 2021-02-23 | — | — | US | disclosed |
| US-10869863-B2 | Multi-arm polymeric targeting anti-cancer conjugate | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-12-22 | — | — | US | disclosed |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2019040647-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2019-02-28 | — | — | WO | disclosed |
| US-5599791-A | BACTERICIDE ACTIVE AGAINST GRAMNEGATIVE AND GRAMPOSITIVE BACTERIA | GRUPPO LEPETIT SPA (IT) | 1997-02-04 | — | — | US | disclosed |
| WO-1996020918-A1 | HYDROXAMIC ACID-CONTAINING INHIBITORS OF MATRIX METALLOPROTEASES | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1992012172-A9 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS | — | 1996-04-04 | — | — | WO | disclosed |
| EP-0565567-B1 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS | LEPETIT SPA (IT) | 1995-01-18 | — | — | EP | disclosed |
| EP-0565567-A1 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS. | LEPETIT SPA (IT) | 1993-10-20 | — | — | EP | disclosed |
| WO-1992012172-A1 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS | GRUPPO LEPETIT S.P.A. (IT) | 1992-07-23 | — | — | WO | disclosed |
| EP-0494078-A1 | Amides of antibiotic ge 2270 factors | GRUPPO LEPETIT S.p.A. (IT) | 1992-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163403-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, RNASE1, TP53 | DPP4 3472/4885PREP 1942/4885FAP 1120/4885 |
| US-10869863-B2 | Multi-arm polymeric targeting anti-cancer conjugate | TOP2A, TOP1, ABCG2 | DPP4 4687/4885PREP 4255/4885FAP 4171/4885 |
| US-11529338-B2 | Compositions and methods for treating cancer | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | DPP4 4257/4885PREP 2965/4885FAP 2189/4885 |
| US-20200188373-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CHRNB2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNMT | DPP4 4257/4885PREP 2965/4885FAP 2189/4885 |
| US-20190194124-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TSG101, TP53, RNASE1 | DPP4 3547/4885PREP 2243/4885FAP 1036/4885 |
| US-10927070-B2 | Compositions and methods for treating cancer | TSG101, RNASE1, TP53 | DPP4 3472/4885PREP 1942/4885FAP 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.